What's happening
This bill decriminalizes the possession of buprenorphine in New York by removing it from the penal law's controlled substances list.
Why it matters
Removes criminal penalties for possessing buprenorphine. , which is a key medication for treating opioid use disorder—this could make it easier for people to access and use the medication legally, supporting harm reduction and public health efforts.
Reduces barriers for individuals seeking addiction treatment. , as fear of arrest or prosecution for possessing their medication can discourage people from starting or continuing evidence-based treatment.
Shifts law enforcement and judicial resources away from prosecuting substance use disorder patients. , potentially allowing for more focus on serious crimes and furthering the movement away from punitive drug policies toward a healthcare-oriented approach.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Headline styles
Decriminalize Buprenorphine Possession
Plain English, a few words. Used as the page title.
Sponsors
History
- Referred to codes
- Referred to codes
Companion bill
The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.
Decriminalize Buprenorphine Possession
In Assembly Committee · Codes · Sponsor Linda Rosenthal
Full text
1 pageUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
2524
2021-2022 Regular Sessions
IN SENATE
January 21, 2021
Introduced by Sen. RIVERA -- read twice and ordered printed, and when printed to be committed to the Committee on Codes
AN ACT to amend the penal law, in relation to decriminalizing the possession of buprenorphine
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. Subdivisions 5 and 8 of section 220.00 of the penal law, subdivision 5 as amended by chapter 537 of the laws of 1998 and subdivision 8 as amended by section 18 of part C of chapter 447 of the laws of 2012, are amended to read as follows:
5. "Controlled substance" means any substance listed in schedule I, II, III, IV or V of section thirty-three hundred six of the public health law other than buprenorphine and marihuana, but including concentrated cannabis as defined in paragraph (a) of subdivision four of section thirty-three hundred two of such law.
8. "Narcotic preparation" means any controlled substance listed in schedule II(b-1), III(d) or III(e) other than buprenorphine.
§ 2. This act shall take effect on the first of November next succeeding the date on which it shall have become a law.
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD00318-01-1
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Sponsor's memo
Title of bill
An act to amend the penal law, in relation to decriminalizing the possession of buprenorphine
Purpose
This bill would exclude buprenorphine, a medication commonly used to treat opioid use disorder, from the list of controlled substances.
Summary of specific provisions
Section one amends section 220.00 of the penal law.
Section two sets forth the effective date.
Justification
Buprenorphine is an effective medication used to treat opioid use disor- der (OUD). In 2000, the federal Drug Addiction Treatment Act allowed physicians to begin prescribing buprenorphine for treatment of OUD, which provided them with an option other than methadone for the treat- ment and management of OUD. Buprenorphine is classified as a schedule III/IIIN controlled substance because its potential for abuse is marked- ly lower than methadone. Additionally, because patients can self-admin- ister buprenorphine, it does not require patients to travel to doctors, offices or treatment facilities each day for their prescribed dose.
Despite its efficacy, buprenorphine is classified as a controlled substance, meaning that individuals who possess it without a prescription risk criminal prosecution, even if they are using it to treat their own opioid use disorder. While there is a small risk that people may divert and use buprenorphine, the vast majority of use, both subsequent to a prescription and not, is to manage opioid use disorder. We should not discourage this use.
This legislation would place buprenorphine on par with marijuana in 'our schedule of controlled substances and ensure we are not wrongly prose- cuting individuals who are attempting to treat an opioid use disorder.
Legislative history
2019-2020: A.10109 L Rosenthal/No Same-As
Fiscal implications
Undetermined.
Effective date
This act shall take effect immediately.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.